Get notified regarding key financial metrics and revenue changes at OncoMed PharmaceuticalsLearn more
Banner background

Summary - Funding Rounds

Founding Date

2004

Total Funding

$210.2 m

Investors

In total, OncoMed Pharmaceuticals had raised $210.2 m. OncoMed Pharmaceuticals is a subsidiary of Mereo BioPharma

OncoMed Pharmaceuticals Income Statement

OncoMed Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

208.9m28.1m38.4m37.0m13.3m9.7m

Accounts Receivable

70.7m405.0k3.0m

Prepaid Expenses

2.5m1.7m3.3m1.7m1.9m

Inventories

Current Assets

318.7m240.8m231.3m189.6m105.2m63.7m

PP&E

4.6m5.1m4.8m4.5m3.3m623.0k

Total Assets

333.7m247.8m237.9m195.5m110.3m65.1m

Accounts Payable

5.7m4.4m6.7m4.9m2.6m1.8m

Short-term debt

Current Liabilities

62.0m38.5m52.6m55.9m93.1m12.6m

Long-term debt

Total Debt

Total Liabilities

215.6m171.5m234.3m218.5m158.9m16.8m

Common Stock

29.0k30.0k30.0k38.0k38.0k

Additional Paid-in Capital

292.5m300.8m313.3m389.6m403.1m410.0m

Retained Earnings

(174.4m)(224.4m)(309.8m)(412.9m)(452.0m)(361.8m)

Total Equity

118.1m76.4m3.6m(23.0m)(48.6m)48.2m

Financial Leverage

2.8 x3.2 x67 x-8.5 x-2.3 x1.3 x

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

16.2m11.1m26.0m23.4m30.0m29.1m36.3m31.3m84.6m37.8m30.1m39.2m31.9m15.9m14.1m10.6m8.4m

Accounts Receivable

48.0k2.1m315.0k1.3m2.0m2.2m1.7m2.0m348.0k258.0k110.0k416.0k

Prepaid Expenses

1.2m1.9m2.5m2.8m3.6m1.8m1.2m1.8m3.6m2.5m2.8m3.2m3.2m2.4m1.7m1.5m1.9m

Current Assets

57.7m140.6m286.4m269.2m256.1m222.0m201.4m177.3m198.4m176.1m212.7m161.8m135.0m116.4m90.4m81.5m73.2m

PP&E

4.9m4.6m5.0m5.2m5.0m5.1m5.3m5.1m4.9m4.6m4.4m4.2m3.8m3.4m2.9m2.5m2.4m

Total Assets

66.2m145.2m301.9m284.3m268.9m229.0m209.1m184.6m204.9m181.9m218.2m166.9m139.3m120.5m95.1m85.9m77.2m

Accounts Payable

812.0k2.1m2.9m3.0m3.8m3.1m6.1m3.4m3.2m4.5m5.4m3.9m2.1m779.0k704.0k981.0k3.2m

Current Liabilities

30.5m32.3m48.7m50.4m40.9m34.5m37.3m37.7m48.4m54.3m55.5m49.5m39.9m34.3m34.9m33.2m21.3m

Total Liabilities

45.4m44.2m196.1m192.0m179.5m163.7m162.8m159.7m224.7m225.4m221.4m207.7m193.1m182.6m48.8m41.9m25.4m

Common Stock

6.5k28.0k30.0k30.0k30.0k30.0k30.0k30.0k30.0k30.0k37.0k37.0k37.0k38.0k38.0k38.0k38.0k

Preferred Stock

182.8m

Additional Paid-in Capital

4.6m271.1m294.1m296.2m298.7m304.2m306.8m309.8m317.1m321.0m387.2m394.5m396.7m399.1m405.4m407.2m408.9m

Retained Earnings

(166.6m)(170.1m)(188.3m)(203.9m)(209.4m)(239.0m)(260.6m)(285.1m)(337.1m)(364.7m)(390.6m)(435.6m)(450.8m)(461.5m)(359.3m)(363.2m)(357.1m)

Total Equity

(162.0m)101.1m105.8m92.3m89.4m65.3m46.3m24.9m(19.8m)(43.5m)(3.2m)(40.8m)(53.8m)(62.2m)46.3m44.0m51.7m

Financial Leverage

-0.4 x1.4 x2.9 x3.1 x3 x3.5 x4.5 x7.4 x-10.3 x-4.2 x-68.6 x-4.1 x-2.6 x-1.9 x2.1 x2 x1.5 x

OncoMed Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(26.1m)(50.0m)(85.4m)(103.1m)(39.1m)(8.1m)

Depreciation and Amortization

1.4m1.4m1.6m1.8m1.7m1.7m

Accounts Receivable

(70.7m)68.2m2.1m(19.0k)

Accounts Payable

4.9m(1.3m)2.2m(1.8m)(2.3m)(778.0k)

Cash From Operating Activities

144.5m(84.5m)(75.1m)(36.9m)(85.0m)(44.9m)

Purchases of PP&E

(557.0k)(1.8m)(1.4m)(1.2m)(585.0k)(655.0k)

Cash From Investing Activities

(57.8m)(98.4m)83.7m(29.7m)57.3m41.2m

Dividends Paid

Cash From Financing Activities

105.9m2.1m1.8m65.1m4.0m89.0k

Net Change in Cash

192.7m(180.8m)10.3m(1.5m)(23.7m)(3.6m)

Income Taxes Paid

8.2m

OncoMed Pharmaceuticals Ratios

USDQ2, 2013

Financial Leverage

-0.4 x

OncoMed Pharmaceuticals Employee Rating

3.912 votes
Culture & Values
3.8
Work/Life Balance
3.3
Senior Management
3.4
Salary & Benefits
3.3
Career Opportunities
3.3
Source